• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Professional Introduction to Compound with CAS No 600-21-5 and Product Name *H-N-Me-DL-Ala-OH*

H-N-Me-DL-Ala-OH, a derivative of *N-methyl-DL-alanine*, is a compound of significant interest in the field of pharmaceutical chemistry and biotechnology. With a CAS number of 600-21-5, this compound has been extensively studied for its potential applications in drug development and synthetic biology. The structure of *H-N-Me-DL-Ala-OH* consists of an alanine residue with a methyl group at the amino position and an hydroxyl group at the carboxyl end, making it a versatile building block for peptide synthesis and enzyme inhibition studies.

The importance of *H-N-Me-DL-Ala-OH* lies in its ability to mimic natural amino acids while introducing modifications that can enhance stability, bioavailability, and binding affinity. Recent research has highlighted its role in the development of novel antibiotics and antiviral agents, where its structural properties contribute to improved pharmacokinetic profiles. The compound's ability to participate in hydrogen bonding and form stable interactions with biological targets makes it a valuable candidate for designing targeted therapies.

In the realm of peptide mimetics, *H-N-Me-DL-Ala-OH* has been utilized to create constrained peptides that exhibit enhanced metabolic stability. This is particularly relevant in the design of long-acting injectables and oral formulations, where degradation resistance is crucial. Studies have demonstrated that incorporating *N-methyl-DL-alanine* residues into peptide sequences can significantly reduce enzymatic cleavage, thereby prolonging the half-life of therapeutic peptides.

Moreover, *H-N-Me-DL-Ala-OH* has shown promise in the development of enzyme inhibitors. Its structural motif allows for precise tuning of binding interactions with enzymes, making it an effective scaffold for designing molecules that can modulate enzymatic activity. For instance, researchers have leveraged this compound to develop inhibitors targeting proteases involved in inflammatory pathways, offering potential treatments for conditions such as rheumatoid arthritis and cancer.

The synthesis of *H-N-Me-DL-Ala-OH* involves well-established chemical methodologies, including solid-phase peptide synthesis (SPPS) and solution-phase reactions. These techniques ensure high purity and yield, which are critical for pharmaceutical applications. The compound's stability under various storage conditions further enhances its utility in industrial-scale production.

Recent advancements in computational chemistry have also contributed to the optimization of *H-N-Me-DL-Ala-OH*-based drug candidates. Molecular modeling studies have identified key structural features that enhance binding affinity and selectivity against biological targets. These insights have guided the design of next-generation compounds with improved therapeutic efficacy.

In conclusion, *H-N-Me-DL-Ala-OH* represents a significant advancement in pharmaceutical chemistry, offering a versatile scaffold for drug development. Its unique structural properties make it an invaluable tool for designing novel therapeutics with enhanced stability and bioactivity. As research continues to uncover new applications for this compound, its role in addressing complex medical challenges is expected to grow.

• 3913-67-5(H-N-Me-Ala-OH)
• 219755-19-8(2-(1-carboxyethyl)aminopropanoic acid)
• 118333-27-0(D-Alanine,N-(1-methylethyl)-)
• 106327-05-3(2-(carboxymethyl)aminopropanoic acid)
• 103954-11-6(D-Alanine,N-(1-carboxyethyl)-, (R)- (9CI))
• 28413-45-8(L-Alanine, N-methyl-,potassium salt (1:1))
• 125412-04-6(D-Alanine,N-(2-hydroxyethyl)-)
• 29475-64-7(N-Methyl-D-alanine)
• 121307-72-0(Alanine,N-(2-hydroxyethyl)-)
• 101541-15-5(Alanine,N-(1-carboxyethyl)-, (R*,R*)- (9CI))